NeuroMetrix, Inc.

NasdaqCM:NURO Stok Raporu

Piyasa değeri: US$9.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NeuroMetrix Yönetim

Yönetim kriter kontrolleri 4/4

NeuroMetrix CEO'su Shai Gozani, Jun1996 tarihinde atandı, in görev süresi 28.92 yıldır. in toplam yıllık tazminatı $ 475.85K olup, şirket hissesi ve opsiyonları dahil olmak üzere 93.3% maaş ve 6.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.75% ine doğrudan sahiptir ve bu hisseler $ 67.43K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 11.8 yıl ve 14.4 yıldır.

Anahtar bilgiler

Shai Gozani

İcra Kurulu Başkanı

US$475.9k

Toplam tazminat

CEO maaş yüzdesi93.32%
CEO görev süresi28.9yrs
CEO sahipliği0.8%
Yönetim ortalama görev süresi11.8yrs
Yönetim Kurulu ortalama görev süresi14.4yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Oct 20

NeuroMetrix reports Q3 results

NeuroMetrix press release (NASDAQ:NURO): Q3 net loss of $1.6M Revenue of $2M (-4.8% Y/Y).
Seeking Alpha • Sep 23

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth in DPNCheck. The result is rev growth is now accelerating. Clean cap structure and balance sheet with $3.24/share which is sufficient to fund the business to profitability. Potential $15/share fair value in 5 years based on 20x FCF. For those who follow small cap med devices, NURO's business is ~85% SMLR and ~15% ZYXI. Thesis Overview The most profitable investments in microcap stocks are made when businesses reach inflection points, then go on to deliver years of organic growth and inflect to profitability. I believe that NeuroMetrix (NURO) is at that turning point. After a long history of losses and shareholder dilution from spending on R&D that didn’t work and attempts to sell medical devices that were not successful, NURO now has a clean capital structure and balance sheet with a proven business that is scaling with strong unit economics. NURO has a promising medical device called DPNCheck, which is used for early disease detection of diabetic polyneuropathy (DPN) and is sold to Medicare Advantage ((MA)) insurers with >80% of revenue from consumables. They are following the same business model as Semler Scientific (SMLR), who built a strong business by showing MA insurers that early disease detection leads to better patient outcomes, lower cost to serve patients, and increased revenue for the MA insurers through appropriately risk-coding patients. DPNCheck launched in 2011 and has grown at a >20% CAGR in recent years to $7.4m revenue in 2022. That >20% organic growth is set to continue indefinitely at ~80% gross margins. Most importantly, DPNCheck’s go-to-market is very efficient because they sell at the top level to UNH and HUM, who then push down to their organization. DPNCheck’s consistent growth and strong unit economics has been masked by NURO’s Quell product which the company sells direct-to-consumer as an over-the-counter (OTC) medical device for pain management. The company created a slick product that works well and grew it to ~$14m of revenue in 2017, but had to spend aggressively on online advertising and TV ads to get that growth (negative unit economics). In 2018, management realized their market efforts were not going to pay off for Quell because the market for TENS-like devices is too crowded, so they stopped advertising. That led to revenue declining to <$2m in 2022, which is now mostly consumable pads that are ordered by customers and paid through credit card (no insurance pay). Management pivoted the strategy for their Quell device to focusing on gaining breakthrough designation by the FDA for patients with Fibromyalgia. 10 million Americans suffer from debilitating pain from Fibromyalgia. Quell may receive FDA clearance for the device for patients with Fibromyalgia in late 2022 and begin marketing to physicians in early 2023. Having a physician prescription means they can pursue insurance reimbursement which results in a much, much higher revenue per device than selling in the highly competitive over-the-counter market. Zynex sells a prescription pain management device, but sells primarily through physical therapists and does not have specific indications or data supporting efficacy, like Quell does. The takeaways are that NURO’s revenue growth is accelerating. After revenue declines in 2018-2020 from unprofitable Quell OTC revenue falling, NURO grew 12% in 2021 and will grow 12% in 2022. I expect revenue growth to accelerate to >20% and maintain that growth for several years, primarily from DPNCheck. After significant losses from Quell advertising, NURO raised highly dilutive preferred capital in the 2016-2018 range (please refer to NURO's form 10-K filings for details). After cleaning up the cap structure, NURO raised over $20m through DRIP equity raises (selling shares directly into the market) in 2020 and 2021 (including some very attractive sales prices last year when the stock price spiked >$10/share). All this leads to an ugly and messy past, in which the share count has gone way up and the stock price way down. However, I believe that evaluating the business based on current facts, shows that NURO is an undervalued med device company that is well capitalized to pursue this growth. The company now has a clean capital structure with 7.1m shares and 0.5m options for management, no debt, no preferred, no warrants, and $23m of cash. I expect NURO to burn $3.8m in 2022, $2.7m in 2023, $1.7m in 2024, and $0.2m in 2025. Then it should start generating cash, with +$2.1m in 2026, +$4.9m in 2027. I model trough cash of $16m in 2025. On profitability, I expect the business will generate $5m of free cash flow in 2027 and be worth 20x FCF plus net cash, which gives a value of $15/share. Studying Semler’s history, once the business crossed $14m in revenue, it inflected to profitability and never looked back. DPNCheck currently has $7.4m in revenue, and I expect it to cross that threshold exiting 2025. SMLR has proven how strong the unit economics are in this business with 37% EBITDA margins in 2Q22. Revenue Mix Shift Well Underway Higher quality, more profitable DPNCheck revenue is replacing negative margin Quell revenue (when including expensive marketing spend in the past). As rev mix continues to shift, the growth will accelerate and the business will reach profitability.
Seeking Alpha • Jul 21

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix press release (NASDAQ:NURO): Q2 GAAP EPS of -$0.17. Revenue of $2.1M (-5.0% Y/Y).
Analiz Makalesi • May 11

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jan 19

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 09

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

NeuroMetrix is a medical devices company with three commercialized products. The Company says it was spun off from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company has active R&D programs to expand into new indications and improve existing technologies.
Analiz Makalesi • Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, NeuroMetrix...
Analiz Makalesi • Jan 27

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Tazminat Analizi

Shai Gozani'un ücretlendirmesi NeuroMetrix'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2024n/an/a

-US$8m

Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$476kUS$444k

-US$7m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$5m

Dec 31 2022US$645kUS$415k

-US$4m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$558kUS$415k

-US$2m

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$1m

Dec 31 2020US$181kUS$181k

-US$2m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$775kUS$422k

-US$4m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

US$908k

Dec 31 2018US$478kUS$415k

US$24k

Tazminat ve Piyasa: Shai 'ın toplam tazminatı ($USD 475.85K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 652.98K ).

Tazminat ve Kazançlar: Shai 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Shai Gozani (59 yo)

28.9yrs
Görev süresi
US$475,850
Tazminat

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been President since 2002 and Chief Executive Officer since 1997 and Secretary July 2008. He has been the Chairman of the Board at...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Shai Gozani
Founder28.9yrsUS$475.85k0.75%
$ 67.4k
Thomas Higgins
Senior VP15.7yrsUS$371.60k0.57%
$ 51.6k
Xuan Kong
Chief Data Scientist7.9yrsVeri yokVeri yok
Susan Bell
Senior Vice President of Population Health & Value Based Care3.6yrsVeri yokVeri yok
11.8yrs
Ortalama Görev Süresi

Deneyimli Yönetim: NURO 'un yönetim ekibi deneyimli ve deneyimlidir ( 11.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Shai Gozani
Founder28.9yrsUS$475.85k0.75%
$ 67.4k
Nancy Katz
Independent Director14.4yrsUS$105.00k0.37%
$ 33.1k
David Goodman
Independent Director20.9yrsUS$110.00k0.37%
$ 33.1k
Joshua Horowitz
Independent Director1.1yrsVeri yok1.23%
$ 110.4k
David Van Avermaete
Independent Director11.7yrsUS$105.00k0.37%
$ 33.1k
14.4yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: NURO 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/05/01 19:07
Gün Sonu Hisse Fiyatı2025/05/01 00:00
Kazançlar2024/12/31
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

NeuroMetrix, Inc. 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Andrew FeinH.C. Wainwright & Co.
Anthony VendettiMaxim Group